Document:

Exhibit 10.9

INDEMNITY AGREEMENT

 

THIS INDEMNITY AGREEMENT (this “Agreement”)
is made as of [    ], 2021, by and between Medicus Sciences Acquisition Corp., a Cayman Islands exempted company
(the “Company”), and [    ] (“Indemnitee”).

 

WHEREAS, highly competent persons have become more
reluctant to serve publicly-held companies and corporations as directors, officers or in other capacities unless they are provided
with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them
arising out of their service to and activities on behalf of such companies and corporations;

 

WHEREAS, the Board of Directors of the Company (the
 “Board”) has determined that, in order to attract and retain qualified individuals, the Company will
attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its
subsidiaries from certain liabilities. The amended and restated memorandum and articles of association of the Company (the “Articles”)
provide for the indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification
pursuant to applicable Cayman Islands law. The Articles provide that the indemnification provisions set forth therein are not exclusive,
and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons
with respect to indemnification, hold harmless, exoneration, advancement and reimbursement rights;

 

WHEREAS, the uncertainties relating to such insurance
and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased
difficulty in attracting and retaining such persons is detrimental to the best interests of the Company’s shareholders and
that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary
for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses on behalf of, such
persons to the fullest extent permitted by applicable law and the Articles so that they will serve or continue to serve the Company
free from undue concern that they will not be so protected against liabilities;

 

WHEREAS, this Agreement is a supplement to and in
furtherance of the Articles of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor,
nor to diminish or abrogate any rights of Indemnitee thereunder; and

 

WHEREAS, Indemnitee may not be willing to serve
as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee
is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that
he or she be so indemnified.

 

NOW, THEREFORE, in consideration of the premises
and the covenants contained herein and subject to the provisions of the letter agreement dated as of [    ],
2021, the Company and Indemnitee do hereby covenant and agree as follows:

 

	1.	SERVICES
TO THE COMPANY

 

In consideration of the Company’s covenants and obligations
hereunder, Indemnitee will serve or continue to serve as an officer, director, advisor, key employee or in any other capacity of
the Company, as applicable, for so long as Indemnitee is duly elected or appointed or retained or until Indemnitee tenders his
or her resignation or until Indemnitee is removed. The foregoing notwithstanding, this Agreement shall continue in full force and
effect after Indemnitee has ceased to serve as a director, officer, advisor, key employee or in any other capacity of the Company,
as provided in Section 17. This Agreement, however, shall not impose any obligation on Indemnitee or the Company to continue Indemnitee’s
service to the Company beyond any period otherwise required by applicable law and the Articles or by other agreements or commitments
of the parties, if any.

 

    

     

    

 

	2.	DEFINITIONS

 

As used in this Agreement:

 

(a) References to “agent” shall mean any
person who is or was a director, officer or employee of the Company or a subsidiary of the Company or other person authorized by
the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, advisor,
fiduciary or other official of another company, corporation, partnership, limited liability company, joint venture, trust or other
enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.

 

(b) The terms “Beneficial Owner” and
 “Beneficial Ownership” shall have the meanings set forth in Rule 13d-3 promulgated under the Exchange
Act as in effect on the date hereof.

 

(c) “Delaware Court” shall mean the
Court of Chancery of the State of Delaware.

 

(d) A “Change in Control” shall be
deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

(i) Acquisition of Shares by Third Party.
Other than an affiliate of Medicus Sciences Holdings LLC (the “Sponsor”), any Person is or becomes the
Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined
voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors, unless
(1) the change in the relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction
in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, or (2) such
acquisition was approved in advance by the Continuing Directors and such acquisition would not constitute a Change in Control under
part (iii) of this definition;

 

(ii) Change in Board of Directors. Individuals
who, as of the date hereof, constitute the Board, and any new director whose election by the Board or nomination for election by
the Company’s shareholders was approved by a vote of at least two thirds of the directors then still in office who were directors
on the date hereof or whose election or nomination for election was previously so approved (collectively, the “Continuing
Directors”), cease for any reason to constitute at least a majority of the members of the Board;

 

(iii) Corporate Transactions. The effective
date of a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, involving
the Company and one or more businesses (a “Business Combination”), in each case, unless, following such
Business Combination: (1) all or substantially all of the individuals and entities who were the Beneficial Owners of securities
entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially own, directly
or indirectly, more than 51% of the combined voting power of the then outstanding securities of the Company entitled to vote generally
in the election of directors resulting from such Business Combination (including, without limitation, a company or corporation
which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly
or through one or more Subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business
Combination, of the securities entitled to vote generally in the election of directors; (2) other than an affiliate of the Sponsor,
no Person (excluding any company or corporation resulting from such Business Combination) is the Beneficial Owner, directly or
indirectly, of 15% or more of the combined voting power of the then outstanding securities entitled to vote generally in the election
of directors of the surviving company or corporation except to the extent that such ownership existed prior to the Business Combination;
and (3) at least a majority of the board of directors of the company or corporation resulting from such Business Combination were
Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business
Combination;

 

(iv) Liquidation. The approval by the
shareholders of the Company of a complete liquidation of the Company or an agreement or series of agreements for the sale or
disposition by the Company of all or substantially all of the Company’s assets, other than factoring the
Company’s current receivables or escrows due (or, if such approval is not required, the decision by the Board to
proceed with such a liquidation, sale, or disposition in one transaction or a series of related transactions); or

 

    2

     

    

 

(v) Other Events. There occurs any other
event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response
to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject
to such reporting requirement.

 

(e) “Corporate Status” describes the
status of a person who is or was a director, officer, trustee, general partner, manager, managing member, fiduciary, employee or
agent of the Company or of any other Enterprise which such person is or was serving at the request of the Company.

 

(f) “Disinterested Director” shall
mean a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by
Indemnitee.

 

(g) “Enterprise” shall mean the Company
and any other company or corporation, constituent company or corporation (including any constituent of a constituent) absorbed
in a consolidation or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company,
partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request
of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent.

 

(h) “Exchange Act” shall mean the
Securities Exchange Act of 1934, as amended.

 

(i) “Expenses” shall include all direct
and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all reasonable attorneys’
fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators
and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax
transmission charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting,
defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or
otherwise participating in, a Proceeding, including reasonable compensation for time spent by the Indemnitee for which he or she
is not otherwise compensated by the Company or any third party. Expenses also shall include Expenses incurred in connection with
any appeal resulting from any Proceeding, including without limitation the principal, premium, security for, and other costs relating
to any cost bond, supersedeas bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in
settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(j) References to “fines” shall include
any excise tax assessed on Indemnitee with respect to any employee benefit plan.

 

(k) References to “serving at the request of the
Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company which imposes
duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee benefit plan,
its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in
the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted
in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

(l) “Independent Counsel” shall
mean a law firm or a member of a law firm with significant experience in matters of corporate law and that neither presently
is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to
either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees
under similar indemnification agreements); or (ii) any other party to the Proceeding giving rise to a claim for
indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any
person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in
representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement.

 

    3

     

    

 

(m) The term “Person” shall have the
meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however, that “Person”
shall exclude: (i) the Company; (ii) any Subsidiaries of the Company; (iii) any employment benefit plan of the Company or of a
Subsidiary of the Company or of any company or corporation owned, directly or indirectly, by the shareholders of the Company in
substantially the same proportions as their ownership of shares of the Company; and (iv) any trustee or other fiduciary holding
securities under an employee benefit plan of the Company or of a Subsidiary of the Company or of a company or corporation owned
directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership of shares of
the Company.

 

(n) The term “Proceeding” shall include
any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation,
inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company
or otherwise and whether of a civil (including intentional or unintentional tort claims), criminal, administrative or investigative
or related nature, in which Indemnitee was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee
is or was a director or officer of the Company, by reason of any action (or failure to act) taken by him or her or of any action
(or failure to act) on his or her part while acting as a director or officer of the Company, or by reason of the fact that he or
she is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary,
employee or agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or expense
is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement.

 

(o) The term “Subsidiary,” with respect
to any Person, shall mean any company or corporation, limited liability company, partnership, joint venture, trust or other entity
of which a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by
that Person.

 

(p) The phrase “to the fullest extent permitted
by applicable law and the Articles” shall include, but not be limited to: (a) to the fullest extent authorized or
permitted by the provision of applicable Cayman Islands law that authorizes or contemplates additional indemnification by agreement,
or the corresponding provision of any amendment to or replacement of applicable Cayman Islands law, and (b) to the fullest extent
authorized or permitted by any amendments to or replacements of applicable Cayman Islands law adopted after the date of this Agreement
that increase the extent to which a company or corporation may indemnify its officers and directors.

 

	3.	INDEMNITY IN THIRD-PARTY PROCEEDINGS

 

To the fullest extent permitted by applicable law and the
Articles, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this
Section 3 if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or
otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor by
reason of Indemnitee’s Corporate Status. Pursuant to this Section 3, Indemnitee shall be indemnified, held harmless and
exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all
interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines,
penalties and amounts paid in settlement) actually, and reasonably incurred by Indemnitee or on his or her behalf in
connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he
or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal
Proceeding, had no reasonable cause to believe that his or her conduct was unlawful; provided, in no event shall Indemnitee
be entitled to be indemnified, held harmless or advanced any amounts hereunder in respect of any Expenses, judgments,
liabilities, fines, penalties and amounts paid in settlement (if any) that Indemnitee may incur by reason of his or her own
actual fraud or intentional misconduct. Indemnitee shall not be found to have committed actual fraud or intentional
misconduct for any purpose of this Agreement unless or until a court of competent jurisdiction shall have made a finding to
that effect.

 

    4

     

    

 

	4.	INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY

 

To the fullest extent permitted by applicable law and the Articles,
the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 4 if Indemnitee
was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding by or
in the right of the Company to procure a judgment in its favor by reason of Indemnitee’s Corporate Status. Pursuant to this
Section 4, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred
by him or her or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted
in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification,
hold harmless or exoneration for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which
Indemnitee shall have been finally adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to
the extent that any court in which the Proceeding was brought or the Delaware Court shall determine upon application that, despite
the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to
indemnification, to be held harmless or to exoneration.

 

	5.	INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL

 

Notwithstanding any other provisions of this Agreement, but
subject to Section 27, to the extent that Indemnitee was or is, by reason of Indemnitee’s Corporate Status, a party to (or
a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter
therein, in whole or in part, the Company shall, to the fullest extent permitted by applicable law and the Articles, indemnify,
hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith.
If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but
less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent permitted by applicable law
and the Articles, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him
or her or on his or her behalf in connection with each successfully resolved claim, issue or matter. If Indemnitee is not wholly
successful in such Proceeding, the Company also shall, to the fullest extent permitted by applicable law and the Articles, indemnify,
hold harmless and exonerate Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related
to any claim, issue, or matter on which Indemnitee was successful. For purposes of this Section 5 and without limitation, the termination
of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful
result as to such claim, issue or matter.

 

	6.	INDEMNIFICATION FOR EXPENSES OF A WITNESS

 

Notwithstanding any other provision of this Agreement, but subject
to Section 27, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness or deponent in any Proceeding
to which Indemnitee is not a party or threatened to be made a party, he or she shall, to the fullest extent permitted by applicable
law and the Articles, be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him
or her or on his or her behalf in connection therewith.

 

	7.	ADDITIONAL INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS

 

Notwithstanding any limitation in Sections 3, 4 or 5, but
subject to Section 27, the Company shall, to the fullest extent permitted by applicable law and the Articles, indemnify, hold
harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a
Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines,
penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection
with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably
incurred by Indemnitee in connection with the Proceeding. No indemnification, hold harmless or exoneration rights shall be
available under this Section 7 on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty
of loyalty to the Company or its shareholders or is an act or omission not in good faith or which involves intentional
misconduct or a knowing violation of the law.

 

	8.	CONTRIBUTION IN THE EVENT OF JOINT LIABILITY

 

(a) To the fullest extent permissible under applicable law and
the Articles, if the indemnification, hold harmless and/or exoneration rights provided for in this Agreement are unavailable to
Indemnitee in whole or in part for any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or exonerating
Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities, fines,
penalties, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee
to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have at any time
against Indemnitee.

 

    5

     

    

  

(b) The Company shall not enter into any settlement of any Proceeding
in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides
for a full and final release of all claims asserted against Indemnitee.

 

(c) The Company hereby agrees to fully indemnify, hold harmless
and exonerate Indemnitee from any claims for contribution which may be brought by officers, directors or employees of the Company
other than Indemnitee who may be jointly liable with Indemnitee. Indemnitee shall seek payments or advances from the Company only
to the extent that such payments or advances are unavailable from any insurance policy of the Company covering Indemnitee.

 

	9.	EXCLUSIONS

 

Notwithstanding any provision in this Agreement, but subject
to Section 27, the Company shall not be obligated under this Agreement to make any indemnification, advance Expenses, hold harmless
or exoneration payment in connection with any claim made against Indemnitee:

 

(a) for which payment has actually been received by or on behalf
of Indemnitee under any insurance policy or other indemnity or advancement provision, except with respect to any excess beyond
the amount actually received under any insurance policy, contract, agreement, other indemnity or advancement provision or otherwise;

 

(b) for an accounting of profits made from the purchase and
sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act
(or any successor rule) or similar provisions of state statutory law or common law; or

 

(c) except as otherwise provided in Sections 14(f) and (g) hereof,
prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including
any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees
or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or
(ii) the Company provides the indemnification, hold harmless or exoneration payment, in its sole discretion, pursuant to the powers
vested in the Company under applicable law and the Articles.

 

	10.	ADVANCES OF EXPENSES; DEFENSE OF CLAIM

 

(a) Notwithstanding any provision of this Agreement to the
contrary, but subject to Section 27, and to the fullest extent not prohibited by applicable law and the Articles, the Company
shall pay the Expenses incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three
months) in connection with any Proceeding within ten (10) days after the receipt by the Company of a statement or statements
requesting such advances from time to time, prior to the final disposition of any Proceeding. Advances shall, to the fullest
extent permitted by applicable law and the Articles, be unsecured and interest free. Advances shall, to the fullest extent
permitted by applicable law and the Articles, be made without regard to Indemnitee’s ability to repay the Expenses and
without regard to Indemnitee’s ultimate entitlement to be indemnified, held harmless or exonerated under the other
provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing a Proceeding to
enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support
the advances claimed. To the fullest extent required by applicable law and the Articles, such payments of Expenses in advance
of the final disposition of the Proceeding shall be made only upon the Company’s receipt of an undertaking, by or on
behalf of Indemnitee, to repay the advanced amounts to the extent that it is ultimately determined that Indemnitee is not
entitled to be indemnified by the Company under the provisions of this Agreement, applicable law and the Articles or
otherwise. If it shall be determined by a final judgment or other final adjudication that Indemnitee was not so entitled to
indemnification, any advancement shall be returned to the Company (without interest) by the Indemnitee. This Section 10(a)
shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration payment is
excluded pursuant to Section 9, but shall apply to any Proceeding referenced in Section 9(b) prior to a final determination
that Indemnitee is liable therefor.

 

(b) The Company will be entitled to participate in the Proceeding
at its own expense.

 

(c) The Company shall not settle any action, claim or Proceeding
(in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation on Indemnitee without Indemnitee’s
prior written consent. 

 

    6

     

    

 

	11.	PROCEDURE FOR NOTIFICATION AND APPLICATION FOR INDEMNIFICATION

 

(a) Indemnitee agrees to notify promptly the Company in writing
upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding,
claim, issue or matter therein which may be subject to indemnification, hold harmless or exoneration rights, or advancement of
Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation
which it may have to Indemnitee under this Agreement, or otherwise.

 

(b) Indemnitee may deliver to the Company a written application
to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement. Such application(s) may be delivered from
time to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion. Following such a written application
for indemnification by Indemnitee, Indemnitee’s entitlement to indemnification shall be determined according to Section 12(a)
of this Agreement.

 

	12.	PROCEDURE UPON APPLICATION FOR INDEMNIFICATION

 

(a) A determination, if required by applicable law and the
Articles, with respect to Indemnitee’s entitlement to indemnification shall be made in the specific case by one of the
following methods, which shall be at the election of Indemnitee: (i) by a majority vote of the Disinterested Directors, even
though less than a quorum of the Board, (ii) by a committee of such directors designated by majority vote of such directors,
(iii) if there are no Disinterested Directors or if such directors so direct, by Independent Counsel in a written opinion to
the Board, a copy of which shall be delivered to Indemnitee, or (iv) by vote of the shareholders by ordinary resolution. The
Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to
indemnification, including a description of any reason or basis for which indemnification has been denied. If it is so
determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after
such determination. Indemnitee shall reasonably cooperate with the person, persons or entity making such determination with
respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon
reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure
and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses
(including reasonable attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person,
persons or entity making such determination shall be borne by the Company (irrespective of the determination as to
Indemnitee’s entitlement to indemnification) and the Company hereby agrees to indemnify and to hold Indemnitee harmless
therefrom.

 

(b) In the event the determination of entitlement to indemnification
is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in
this Section 12(b). The Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection
be made by the Board), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel
so selected and certifying that the Independent Counsel so selected meets the requirements of “Independent Counsel”
as defined in Section 2 of this Agreement. If the Independent Counsel is selected by the Board, the Company shall give written
notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected and certifying that the Independent
Counsel so selected meets the requirements of “Independent Counsel” as defined in Section 2 of this Agreement. In either
event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have
been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however,
that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements
of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity
the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel.
If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel
unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without
merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section
11(b) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition
the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s
selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Delaware Court,
and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel
under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this
Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the
applicable standards of professional conduct then prevailing).

 

(c) The Company agrees to pay the reasonable fees and expenses
of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel against any and all Expenses, claims,
liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

    7

     

    

 

	13.	PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS

 

(a) In making a determination with respect to entitlement to
indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to
indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(b)
of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by
any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including
by the Disinterested Directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant
to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct,
nor an actual determination by the Company (including by the Disinterested Directors or Independent Counsel) that Indemnitee has
not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met
the applicable standard of conduct.

 

(b) If the person, persons or entity empowered or selected
under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a
determination within thirty (30) days after receipt by the Company of the request therefor, the requisite determination of
entitlement to indemnification shall, to the fullest extent permitted by applicable law and the Articles, be deemed to have
been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material
fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in
connection with the request for indemnification, or (ii) a final judicial determination that any or all such indemnification
is expressly prohibited under applicable law and the Articles; provided, however, that such 30-day period may be extended for
a reasonable time, not to exceed an additional fifteen (15) days, if the person, persons or entity making the determination
with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of
documentation and/or information relating thereto.

 

(c) The termination of any Proceeding or of any claim, issue
or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not
(except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification
or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in
or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable
cause to believe that his or her conduct was unlawful.

 

(d) For purposes of any determination of good faith, Indemnitee
shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise,
including financial statements, or on information supplied to Indemnitee by the directors, manager, or officers of the Enterprise
in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee of the Board or any
director, trustee, general partner, manager or managing member, or on information or records given or reports made to the Enterprise,
its Board, any committee of the Board or any director, trustee, general partner, manager or managing member, by an independent
certified public accountant or by an appraiser or other expert selected by the Enterprise, its Board, any committee of the Board
or any director, trustee, general partner, manager or managing member. The provisions of this Section 13(d) shall not be deemed
to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable
standard of conduct set forth in this Agreement.

 

(e) The knowledge and/or actions, or failure to act, of any
other director, officer, trustee, partner, manager, managing member, fiduciary, agent or employee of the Enterprise shall not be
imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

    8

     

    

 

	14.	REMEDIES OF INDEMNITEE

 

(a) In the event that (i) a determination is made pursuant
to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses,
to the fullest extent permitted by applicable law and the Articles, is not timely made pursuant to Section 10 of this Agreement,
(iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within
thirty (30) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made
pursuant to Sections 5, 6, 7 or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the
Company of a written request therefor, (v) a contribution payment is not made in a timely manner pursuant to Section 8 of this
Agreement, (vi) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within ten (10) days after
a determination has been made that Indemnitee is entitled to indemnification, or (vii) payment to Indemnitee pursuant to any hold
harmless or exoneration rights under this Agreement or otherwise is not made in accordance with this Agreement within ten (10)
days after receipt by the Company of a written request therefor, Indemnitee shall be entitled to an adjudication by the Delaware
Court to such indemnification, hold harmless, exoneration, contribution or advancement rights. Alternatively, Indemnitee, at his
or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration
Rules and Mediation Procedures of the American Arbitration Association. Except as set forth herein, the Commercial Arbitration
Rules and Mediation Procedures of the American Arbitration Association shall apply to any such arbitration. The Company shall
not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

 

(b) In the event that a determination
shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial
proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration,
on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.

 

(c) In any judicial proceeding or arbitration commenced pursuant
to this Section 14, Indemnitee shall be presumed to be entitled to be indemnified, held harmless, exonerated to receive advancement
of Expenses under this Agreement and the Company shall have the burden of proving Indemnitee is not entitled to be indemnified,
held harmless, exonerated and to receive advancement of Expenses, as the case may be, and the Company may not refer to or introduce
into evidence any determination pursuant to Section 12(a) of this Agreement adverse to Indemnitee for any purpose. If Indemnitee
commences a judicial proceeding or arbitration pursuant to this Section 14, Indemnitee shall not be required to reimburse the Company
for any advances pursuant to Section 10 until a final determination is made with respect to Indemnitee’s entitlement to indemnification
(as to which all rights of appeal have been exhausted or lapsed).

 

(d) If a determination shall have been made pursuant to Section
12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any
judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material
fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection
with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law and the Articles.

 

(e) The Company shall be precluded from asserting in any judicial
proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not
valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by
all the provisions of this Agreement.

 

    9

     

    

 

(f) The Company shall indemnify and hold harmless Indemnitee
to the fullest extent permitted by applicable law and the Articles against all Expenses and, if requested by Indemnitee, shall
(within ten (10) days after the Company’s receipt of such written request) pay to Indemnitee, to the fullest extent permitted
by applicable law, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought
by Indemnitee: (i) to enforce his or her rights under, or to recover damages for breach of, this Agreement or any other indemnification,
hold harmless, exoneration, advancement or contribution agreement or provision of the Articles now or hereafter in effect; or (ii)
for recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless of the outcome
and whether Indemnitee ultimately is determined to be entitled to such indemnification, hold harmless or exoneration right, advancement,
contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by Indemnitee
in good faith).

 

(g) Interest shall be paid by the Company to Indemnitee at the
legal rate under New York law for amounts which the Company indemnifies, holds harmless or exonerates, or advances, or is obliged
to indemnify, hold harmless or exonerate or advance for the period commencing with the date on which Indemnitee requests indemnification,
to be held harmless, exonerated, contribution, reimbursement or advancement of any Expenses and ending with the date on which such
payment is made to Indemnitee by the Company.

 

	15.	SECURITY

 

Notwithstanding anything herein to the contrary, but subject
to Section 27, to the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time
provide security to Indemnitee for the Company’s obligations hereunder through an irrevocable bank line of credit, funded
trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written
consent of Indemnitee.

 

	16.	NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION; PRIORITY OF OBLIGATIONS

 

(a) The rights of Indemnitee as provided by this Agreement shall
not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law and the Articles,
the Articles, any agreement, a vote of shareholders or a resolution of directors, or otherwise. No amendment, alteration or repeal
of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of
any Proceeding (regardless of when such Proceeding is first threatened, commenced or completed) or claim, issue or matter therein
arising out of, or related to, any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment,
alteration or repeal. To the extent that a change in applicable law and the Articles, whether by statute or judicial decision,
permits greater indemnification, hold harmless or exoneration rights or advancement of Expenses than would be afforded currently
under the Articles or this Agreement, then this Agreement (without any further action by the parties hereto) shall automatically
be deemed to be amended to require that the Company indemnifies the Indemnitee to the fullest extent permitted by applicable law
and the Articles. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other
right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing
at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other right or remedy.

 

(b) The Articles permit the Company to purchase and maintain
insurance or furnish similar protection or make other arrangements including, but not limited to, providing a trust fund, letter
of credit, or surety bond (“Indemnification Arrangements”) on behalf of Indemnitee against any liability
asserted against him or her or incurred by or on behalf of him or in such capacity as a director, officer, employee or agent of
the Company, or arising out of his or her status as such, whether or not the Company would have the power to indemnify him or her
against such liability under the provisions of this Agreement and the Articles. The purchase, establishment, and maintenance of
any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company or of Indemnitee
under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee
shall not in any way limit or affect the rights and obligations of the Company or the other party or parties thereto under any
such Indemnification Arrangement.

 

    10

     

    

 

(c) To the extent that the Company maintains an insurance policy
or policies providing liability insurance for directors, officers, trustees, partners, managers, managing members, fiduciaries,
employees, or agents of the Company or of any other Enterprise which such person serves at the request of the Company, Indemnitee
shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available
for any such director, officer, trustee, partner, managers, managing member, fiduciary, employee or agent under such policy or
policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant
(as a witness, deponent or otherwise), the Company has director and officer liability insurance in effect, the Company shall give
prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company
shall thereafter use commercially reasonable efforts to cause such insurers to pay, on behalf of Indemnitee, all amounts payable
as a result of such Proceeding in accordance with the terms of such policies.

 

(d) In the event of any payment under this Agreement, the Company,
to the fullest extent permitted by applicable law and the Articles, shall be subrogated to the extent of such payment to all of
the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights,
including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. No such payment
by the Company shall be deemed to relieve any insurer of its obligations.

 

(e) The Company’s obligation to indemnify, hold
harmless, exonerate or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a
director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent of any other Enterprise shall be
reduced by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments or
advancement of expenses from such Enterprise. Notwithstanding any other provision of this Agreement to the contrary, but
subject to Section 27, (i) Indemnitee shall have no obligation to reduce, offset, allocate, pursue or apportion any
indemnification, hold harmless, exoneration, advancement, contribution or insurance coverage among multiple parties
possessing such duties to Indemnitee prior to the Company’s satisfaction and performance of all its obligations under
this Agreement, and (ii) the Company shall perform fully its obligations under this Agreement without regard to whether
Indemnitee holds, may pursue or has pursued any indemnification, advancement, hold harmless, exoneration, contribution or
insurance coverage rights against any person or entity other than the Company.

 

(f) Notwithstanding anything contained herein, the Company is
the primary indemnitor, and any indemnification or advancement obligation of the Sponsor or its affiliates or members or any other
Person is secondary.

 

	17.	DURATION OF AGREEMENT

 

All agreements and obligations of the Company contained herein
shall continue during the period Indemnitee serves as a director or officer of the Company or as a director, officer, trustee,
partner, manager, managing member, fiduciary, employee or agent of any other company or corporation, partnership, joint venture,
trust, employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter
so long as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding commenced
by Indemnitee pursuant to Section 14 of this Agreement) by reason of his or her Corporate Status, whether or not he or she is acting
in any such capacity at the time any liability or expense is incurred for which indemnification or advancement can be provided
under this Agreement.

 

	18.	SEVERABILITY

 

If any provision or provisions of this Agreement shall be held
to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining
provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable)
shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by applicable
law and the Articles; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable
law and the Articles and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible,
the provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable)
shall be construed so as to give effect to the intent manifested thereby.

 

    11

     

    

 

	19.	ENFORCEMENT AND BINDING EFFECT

 

(a) The Company expressly confirms and agrees that it has entered
into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, officer
or key employee of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director,
officer or key employee of the Company.

 

(b) Without limiting any of the rights of Indemnitee under the
Articles of the Company as they may be amended from time to time, this Agreement constitutes the entire agreement between the parties
hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied,
between the parties hereto with respect to the subject matter hereof.

 

(c) The indemnification, hold harmless, exoneration and
advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by
the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase,
merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company), shall continue
as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or a director, officer,
trustee, general partner, manager, managing member, fiduciary, employee or agent of any other Enterprise at the
Company’s request, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees,
executors and administrators and other legal representatives.

 

(d) The Company shall require and cause any successor (whether
direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business
and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree
to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession
had taken place.

 

(e) The Company and Indemnitee agree herein that a monetary
remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree
that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may, to the fullest
extent permitted by applicable law and the Articles, enforce this Agreement by seeking, among other things, injunctive relief and/or
specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive
relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he or
she may be entitled. The Company and Indemnitee further agree that Indemnitee shall, to the fullest extent permitted by applicable
law and the Articles, be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary
injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The
Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a court of competent
jurisdiction, and the Company hereby waives any such requirement of such a bond or undertaking to the fullest extent permitted
by applicable law and the Articles.

 

	20.	MODIFICATION AND WAIVER

 

No supplement, modification or amendment of this Agreement shall
be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed
or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 

	21.	NOTICES

 

All notices, requests, demands and other communications under
this Agreement shall be in writing and shall be deemed to have been duly given (i) if delivered by hand and receipted for by the
party to whom said notice or other communication shall have been directed, or (ii) if mailed by certified or registered mail with
postage prepaid, on the third (3rd) business day after the date on which it is so mailed:

 

(a) If to Indemnitee, at the address indicated on the signature
page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company.

 

    12

     

    

 

(b) If to the Company, to:

 

Medicus Sciences Acquisition Corp. 

152 West 57th Street, Floor 20

New York, New York 10019

 

with a copy, which shall not constitute notice, to:

 

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas

New York, NY 10105

Attn: Barry I. Grossman, Esq.

 

or to any other address as may have been furnished to Indemnitee
in writing by the Company.

 

	22.	APPLICABLE LAW AND CONSENT TO JURISDICTION

 

This Agreement and the legal relations among the parties shall
be governed by, and construed and enforced in accordance with, the laws of the State of New York, without regard to its conflict
of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, to the
fullest extent permitted by applicable law and the Articles, the Company and Indemnitee hereby irrevocably and unconditionally:
(a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware
Court and not in any other state or federal court in the United States of America or any court in any other country; (b) consent
to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection
with this Agreement; (c) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court; and
(d) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been
brought in an improper or inconvenient forum, or is subject (in whole or in part) to a jury trial. To the fullest extent permitted
by applicable law and the Articles, the parties hereby agree that the mailing of process and other papers in connection with any
such action or proceeding in the manner provided by Section 21 or in such other manner as may be permitted by applicable law and
the Articles, shall be valid and sufficient service thereof.

 

	23.	IDENTICAL COUNTERPARTS

 

This Agreement may be executed in one or more counterparts,
each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.
Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence
of this Agreement.

 

	24.	MISCELLANEOUS

 

The headings of the paragraphs of this Agreement are inserted
for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

	25.	PERIOD OF LIMITATIONS

 

No legal action shall be brought and no cause of action shall
be asserted by or in the right of the Company against Indemnitee, Indemnitee’s spouse, heirs, executors or personal or legal
representatives after the expiration of two years from the date of accrual of such cause of action, and any claim or cause of action
of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year
period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action such shorter
period shall govern.

 

    13

     

    

 

	26.	ADDITIONAL ACTS

 

If for the validation of any of the provisions in this Agreement
any act, resolution, approval or other procedure is required to the fullest extent permitted by applicable law and the Articles,
the Company undertakes to cause such act, resolution, approval or other procedure to be affected or adopted in a manner that will
enable the Company to fulfill its obligations under this Agreement.

 

	27.	WAIVER OF CLAIMS TO TRUST ACCOUNT

 

Notwithstanding anything contained herein to the contrary, Indemnitee
hereby agrees that it does not have any right, title, interest or claim of any kind (each, a “Claim”)
in or to any monies in the trust account established in connection with the Company’s initial public offering for the benefit
of the Company and holders of shares issued in such offering, and hereby waives any Claim it may have in the future as a result
of, or arising out of, any services provided to the Company and will not seek recourse against such trust account for any reason
whatsoever. Accordingly, Indemnitee acknowledges and agrees that any indemnification provided hereto will only be able to be satisfied
by the Company if (i) the Company has sufficient funds outside of the Trust Account to satisfy its obligations hereunder or (ii)
the Company consummates a Business Combination.

 

	28.	MAINTENANCE OF INSURANCE

 

The Company shall use commercially reasonable efforts to obtain
and maintain in effect during the entire period for which the Company is obligated to indemnify the Indemnitee under this Agreement,
one or more policies of insurance with reputable insurance companies to help ensure the Company’s performance of its indemnification
obligations under this Agreement. The Indemnitee shall be covered by such policy or policies in accordance with its or their terms
to the maximum extent of the coverage available for any such director or officer under such policy or policies. In all such insurance
policies, the Indemnitee shall be named as an insured in such a manner as to provide the Indemnitee with the same rights and benefits
as are accorded to the most favorably insured of the Company’s directors and officers.

 

[SIGNATURE PAGE FOLLOWS]

 

    14

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Indemnity
Agreement to be signed as of the day and year first above written.

 

	 	MEDICUS SCIENCES ACQUISITION CORP.
	 	 	 
	 	By:	 
	 	 	Name: 
	 	 	Title: 

 

	 	INDEMNITEE
	 	 
	 	Name:
	 	Address:

 

[Signature Page
to Indemnity Agreement]Exhibit 10.10

 

FORWARD PURCHASE
AGREEMENT

 

This Forward Purchase
Agreement (this “Agreement”) is entered into as of February 2, 2021, by and among Medicus Sciences Acquisition
Corp., a Cayman Islands exempted company (the “Company”), and Altium MSAC, LLC, a Delaware limited liability
company, and Structure Alpha LLC, a Delaware limited liability company (each a “Purchaser”, and collectively,
the “Purchasers”).

 

RECITALS

 

WHEREAS, the Company
was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar
business combination with one or more businesses (a “Business Combination”);

 

WHEREAS, the Company
has filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 (File
No. 333-251674) (such registration statement, as amended from time to time, including to reflect changes in terms, the “Registration
Statement”) for its initial public offering (“IPO”) of 8,000,000 units (or 9,200,000 units
if the IPO over-allotment option is exercised in full), which amounts may be adjusted in connection with the Company’s marketing
efforts relating to the IPO (the units so issued in the IPO, including any units issued in connection with an over-allotment exercise,
are referred to herein as the “Units”), at a price of $10.00 per Unit, each Unit comprised of one Class A
ordinary share of the Company, par value $0.0001 per share (the “Class A Ordinary Share,” and the
Class A Ordinary Shares included in the Units, the “Public Shares”), one-ninth of one redeemable
warrant (the “Outstanding Redeemable Warrants”), where each whole redeemable warrant
is exercisable to purchase one Class A Ordinary Share at an exercise price of $11.50 per share, and a contingent
right to receive at least two-ninths of one redeemable warrant following the Company’s initial business combination (under
certain circumstances and subject to adjustment, pursuant to a contingent rights agreement (the “Contingent Rights
Agreement”)) (the “Distributable Redeemable Warrants” and, together with the Outstanding
Redeemable Warrants, the “Redeemable Warrants”);

 

WHEREAS, following
the closing of the IPO (the “IPO Closing”), the Company will seek to identify and consummate a Business
Combination;

 

WHEREAS, the parties
wish to enter into this Agreement, pursuant to which, at any time subsequent to the date of the consummation of the IPO (but in
no event later than immediately prior to consummation of the Company’s Business Combination (the “Business Combination
Closing”), the Company shall issue and sell to the Purchasers, and the Purchasers shall purchase
in the aggregate from the Company, on a private placement basis and subject to the conditions set forth herein, up to $16,000,000
of units, each consisting of one Class A Ordinary Share and one-third of one warrant, where each whole warrant is exercisable
to purchase one Class A Ordinary Share at an exercise price of $11.50 per share (each, a “Forward Purchase Unit”),
at a purchase price of $10.00 per Forward Purchase Unit (the “Forward Purchase Price”), in accordance
with Section 1 herein and otherwise in accordance with the terms and conditions set forth herein;

 

WHEREAS, in connection
with the IPO, Medicus Sciences Holdings LLC (the “Sponsor”), the sponsor of the Company, and Maxim Group
LLC (“Maxim”), the representative of the several underwriters for the IPO, will purchase in the aggregate
from the Company 4,755,556 warrants (the “Private Placement Warrants”) (assuming the underwriters’
over-allotment option is not exercised) at a price of $0.90 per warrant in a private placement transaction that will close simultaneously
with the IPO Closing;

 

WHEREAS, the Redeemable
Warrants, Private Placement Warrants and Forward Purchase Warrants (as defined below), are governed by the terms of a Warrant Agreement,
dated as of the date hereof (the “Warrant Agreement”), by and between the Company and Continental Stock
Transfer & Trust Company, as warrant agent; and

 

    1 

     

    

 

WHEREAS, proceeds
from the IPO and the sale of the Private Placement Warrants, in an aggregate amount equal to the gross proceeds from the IPO (“Gross
Proceeds”), will be deposited into a trust account for the benefit of the holders of the Public Shares (the “Trust
Account”), and proceeds in excess of the Gross Proceeds, together with the proceeds of the sale of any Forward Purchase
Units prior to the date of the Business Combination Closing, will not be deposited in the Trust Account and will be used by the
Company to pay the expenses of the IPO (including underwriting discounts and commissions, as described in the Registration Statement),
with the remainder held by the Company in its operating account, in each case as described in the Registration Statement.

 

NOW, THEREFORE,
in consideration of the premises, representations, warranties and the mutual covenants contained in this Agreement, and for other
good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree
as follows:

 

AGREEMENT

 

1. Sale and Purchase.

 

(a) Forward
Purchase Units.

 

(i) Maximum
Forward Purchase. At any time subsequent to the date of the consummation of the IPO (but in no event later than immediately
prior to the Business Combination Closing), as described in the Registration Statement and subject to subparagraph (iv) hereof,
the Purchasers shall purchase in the aggregate up to $16,000,000 of Forward Purchase Units (1,600,000 Forward Purchase Units) (the
 “Maximum Forward Purchase”). The Maximum Forward Purchase shall be effectuated, at the Purchasers’
election, in one or more private placements of Forward Purchase Units, at one or more times. The closing of any such private placement
(other than if occurring immediately prior to the Business Combination Closing) shall occur as soon as practicable but no later
than three business days after the Purchasers shall have issued a notice (a “Purchase Election Notice”)
to the Company electing to consummate all or a portion of the Maximum Forward Purchase. The obligation to consummate the Maximum
Forward Purchase set forth in this Section 1(a)(i) shall not be assignable or transferable by the Purchasers
(provided that the individual obligation, as of any date of determination, of each Purchaser to consummate the Maximum Forward
Purchase shall be limited to 50% of the Maximum Forward Purchase (the “Individual Maximum Forward Purchase Obligation”).
In no event shall either Purchaser’s Individual Maximum Forward Purchase Obligation be deemed to include any portion of the
other Purchaser’s Individual Maximum Forward Purchase Obligation. If a partial purchase occurs of the Maximum Forward Purchase
amount by either Purchaser, the remainder of that Purchaser’s Individual Maximum Forward Purchase Obligation will continue
to exist as an obligation of that Purchaser, subject to the terms and conditions of this Agreement.

 

(ii) Each
Forward Purchase Unit will have a purchase price equal to the Forward Purchase Price and will consist of one Class A Ordinary
Share and one-third of one warrant, where each whole warrant is exercisable to purchase one Class A Ordinary Share
at an exercise price of $11.50 per share (the Class A Ordinary Shares included in the Forward Purchase Units are referred
to as the “Forward Purchase Shares”; the warrants included in the Forward Purchase Units are referred
to as the “Forward Purchase Warrants”; and the Forward Purchase Shares, the Forward Purchase Warrants
and the Class A Ordinary Shares underlying the Forward Purchase Warrants are referred to collectively as the “Forward
Purchase Securities”). The Forward Purchase Units will not include any contingent rights, and the Purchasers shall
have no right to receive any Distributable Redeemable Warrants in connection with the Forward Purchase Shares. The terms of the
Forward Purchase Warrants will be set forth in and subject to the Warrant Agreement. Upon the occurrence of a purchase of any or
all of a Purchaser’s Individual Maximum Forward Purchase Obligation, the respective Purchaser will deliver in free and clear
funds (to an account notified by the Company to the Purchaser) the aggregate purchase price therefor and the Company shall issue
the Forward Purchase Units, equal to the amount of such purchase set forth in the relevant Purchase Election Notice.

 

(iii) The
Company shall issue the Forward Purchase Units to each Purchaser in book-entry form, free and clear of any liens or other restrictions
whatsoever (other than those arising under state or federal securities laws), registered in the name of the Purchaser (or its nominee
in accordance with its delivery instructions), or to a custodian designated by the Purchaser, as applicable pursuant to written
instructions delivered by the Purchaser.

 

    2 

     

    

 

(iv) 
The Purchasers shall have no obligation to purchase any Forward Purchase Units unless proceeds from sale of the Forward Purchase
Units are necessary to enable the Company to complete its initial Business Combination.  In that event, the Purchasers’
obligation to purchase the Forward Purchase Units is limited to the lesser of (A) the Maximum Forward Purchase, and (B) the
purchase amount necessary to provide the Company with sufficient funds to consummate its initial Business Combination and to pay
related fees and expenses, after first applying amounts available to the Company from the Trust Account (after paying deferred
underwriting commissions and giving effect to any redemptions of Public Shares) and any other equity financing source obtained
by the Company for such purpose at or prior to the consummation of its initial business combination, plus any additional amounts
mutually agreed by the Company and the target company to be retained by the post-Business Combination company for working capital
or other purposes (the “Required Purchase Amount”). In the event that the Required Purchase Amount is
less than the Maximum Forward Purchase, each Purchaser’s Individual Maximum Forward Purchase Obligation shall be reduced
proportionally, and each Purchaser’s Individual Maximum Forward Purchase Obligation shall be equal to 50% of the Required
Purchase Amount. As long as the Purchasers fulfill their obligation to purchase the Required Purchase Amount, the Purchasers shall
be entitled (but not required) to purchase the full amount of the Maximum Forward Purchase, in their sole discretion.

 

(b) Legends.
Each book entry for the Forward Purchase Units (and the Forward Purchase Shares and the Forward Purchase Warrants) shall contain
a notation, and each certificate (if any) evidencing the Forward Purchase Units (and the Forward Purchase Shares and the Forward
Purchase Warrants) shall be stamped or otherwise imprinted with a legend, in substantially the following form:

 

“THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION,
AND MAY NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT AND LAWS. THE SALE, PLEDGE, HYPOTHECATION, OR TRANSFER OF THE SECURITIES
REPRESENTED HEREBY ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN FORWARD PURCHASE AGREEMENT BY AND AMONG THE HOLDERS AND
THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.”

 

(c) Certificates.
The Company shall cooperate with a Purchaser, at its request, to facilitate the timely preparation and delivery of physical certificates
representing the Forward Purchase Units (and the Forward Purchase Shares and the Forward Purchase Warrants should a Purchaser wish
to separate the Forward Purchase Units into its components) and enable such certificates to be in such denominations or amounts,
as the case may be, as the Purchasers may reasonably request and registered in such names as the Purchasers may request. Any such
physical certificates shall be stamped or otherwise imprinted with a legend substantially in the form set forth in Section 1(b).

 

(d) Legend
Removal. If the Forward Purchase Units (or the Forward Purchase Shares and the Forward Purchase Warrants) are eligible to be
sold without restriction under, and without the Company being in compliance with the current public information requirements of,
Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), then at the Purchasers’
request, the Company will cause the Company’s transfer agent to remove the legend set forth in Section 1(b) and Section 1(c).
In connection therewith, if required by the Company’s transfer agent, the Company will promptly cause an opinion of counsel
to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates and directions
required by the transfer agent that authorize and direct the transfer agent to issue such Forward Purchase Units (or the Forward
Purchase Shares and the Forward Purchase Warrants) without any such legend.

 

2. Representations and Warranties
of the Purchasers. Each Purchaser represents and warrants to the Company as follows, as of the date hereof:

 

(a) Organization
and Power. The Purchaser is duly organized, validly existing, and in good standing under the laws of the jurisdiction of its
formation and has all requisite power and authority to carry on its business as presently conducted and as proposed to be conducted.

 

    3 

     

    

 

(b) Authorization.
The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Purchaser,
will constitute the valid and legally binding obligation of the Purchaser, enforceable against the Purchaser in accordance with
its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and
any other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies, or (iii) to the extent
the indemnification provisions contained in the Registration Rights (as defined below) may be limited by applicable federal or
state securities laws.

 

(c) Governmental
Consents and Filings. No consent, approval, order or authorization of, or registration, qualification, designation, declaration
or filing with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with
the consummation of the transactions contemplated by this Agreement.

 

(d) Compliance
with Other Instruments. The execution, delivery and performance by the Purchaser of this Agreement and the consummation by
the Purchaser of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions
of its organizational documents, (ii) of any instrument, judgment, order, writ or decree to which it is a party or by which
it is bound, (iii) under any note, indenture or mortgage to which it is a party or by which it is bound, (iv) under any
lease, agreement, contract or purchase order to which it is a party or by which it is bound or (v) of any provision of federal
or state statute, rule or regulation applicable to the Purchaser, in each case (other than clause (i)), which would have a
material adverse effect on the Purchaser or its ability to consummate the transactions contemplated by this Agreement.

 

(e) Purchase
Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to
the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Forward Purchase
Units to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or
agent, and not with a view to the resale or distribution of any part thereof in violation of any state or federal securities laws,
and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same in
violation of law (other than as set forth herein). By executing this Agreement, the Purchaser further represents that the Purchaser
does not presently have any contract, undertaking, agreement or arrangement with any Person (other than another Purchaser) to sell,
transfer or grant participations to such Person, with respect to any of the Forward Purchase Units. For purposes of this Agreement,
 “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization, any other entity or any government or any department or agency thereof.

 

(f) Disclosure
of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs
and the terms and conditions of the offering of the Forward Purchase Units, as well as the terms of the Company’s proposed
IPO, with the Company’s management.

 

(g) Restricted
Securities. The Purchaser understands that the offer and sale of the Forward Purchase Units to the Purchaser has not been,
and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the
Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s
representations as expressed herein. The Purchaser understands that the Forward Purchase Units are “restricted securities”
under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Forward Purchase
Units indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration
and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify
the Forward Purchase Units for resale, except as provided herein (the “Registration Rights”). The Purchaser
further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period for the Forward Purchase Units, and on requirements
relating to the Company which are outside of the Purchaser’s control, and which the Company is under no obligation and may
not be able to satisfy. The Purchaser understands that the offering of the Forward Purchase Units is not and is not intended to
be part of the IPO, and that the Purchaser will not be able to rely on the protection of Section 11 of the Securities Act.

 

(h) No
Public Market. The Purchaser understands that no public market now exists for the Forward Purchase Units, and that the Company
has made no assurances that a public market will ever exist for the Forward Purchase Units.

 

    4 

     

    

 

(i) High
Degree of Risk. The Purchaser understands that its agreement to purchase the Forward Purchase Units involves a high degree
of risk which could cause the Purchaser to lose all or part of its investment.

 

(j) Accredited
Investor. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the
Securities Act.

 

(k) No
General Solicitation. Neither the Purchaser, nor, to its knowledge, any of its officers, directors, employees, agents, stockholders
or partners has either directly or indirectly, including, through a broker or finder (i) engaged in any general solicitation,
or (ii) published any advertisement in connection with the offer and sale of the Forward Purchase Units.

 

(l) Residence.
The Purchaser’s principal place of business is the office or offices located at the address of the Purchaser set forth on
the signature page hereof.

 

(m) Adequacy
of Financing. The Purchaser has available to it sufficient funds to satisfy its obligations under this Agreement.

 

(n) Affiliation
of Certain FINRA Members. The Purchaser is neither a person associated nor affiliated with Maxim or, to its actual knowledge,
any other member of the Financial Industry Regulatory Authority (“FINRA”) that is participating in the
IPO.

 

(o) No
Other Representations and Warranties; Non-Reliance. Except for the specific representations and warranties contained in
this Section 2 and in any certificate or agreement delivered pursuant hereto, none of the Purchaser nor any
person acting on behalf of the Purchaser nor any of the Purchaser’s affiliates (the “Purchaser Parties”)
has made, makes or shall be deemed to make any other express or implied representation or warranty with respect to the Purchaser
and this offering, and the Purchaser Parties disclaim any such representation or warranty. Except for the specific representations
and warranties expressly made by the Company in Section 3 of this Agreement and in any certificate or agreement
delivered pursuant hereto, the Purchaser Parties specifically disclaim that they are relying upon any other representations or
warranties that may have been made by the Company, any person on behalf of the Company or any of the Company’s affiliates
(collectively, the “Company Parties”).

 

3. Representations and Warranties
of the Company. The Company represents and warrants to the Purchasers as follows:

 

(a) Organization
and Corporate Power. The Company is a corporation duly incorporated and validly existing and in good standing as a corporation
under the laws of the Cayman Islands and has all requisite corporate power and authority to carry on its business as presently
conducted and as proposed to be conducted. The Company has no subsidiaries.

 

(b) Capitalization.
On the date hereof, the authorized share capital of the Company consists of:

 

(i) 200,000,000
Class A Ordinary Shares, none of which are issued and outstanding.

 

(ii) 20,000,000
Class B Ordinary Shares, 2,323,000 of which are issued and outstanding as of the date hereof (up to 303,000 of which are subject
to forfeiture if the underwriters’ over-allotment option is not exercised). All of the outstanding Class B Ordinary
Shares have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable foreign, federal
and state securities laws.

 

(iii) 1,000,000
preference shares, none of which are issued and outstanding.

 

(c) Authorization.
All corporate action required to be taken by the Company’s Board of Directors and shareholders in order to authorize the
Company to enter into this Agreement and to issue the Forward Purchase Units has been taken or will be taken prior to the closing
of any purchase and sale thereof (each, a “Forward Closing”), including all corporate action required
to authorize the issuance of the related redeemable warrants. All action on the part of the shareholders, directors and officers
of the Company necessary for the execution and delivery of this Agreement, the performance of all obligations of the Company under
this Agreement to be performed as of a Forward Closing, and the issuance and delivery of the Forward Purchase Units has been taken
or will be taken prior to a Forward Closing. This Agreement, when executed and delivered by the Company, shall constitute the valid
and legally binding obligation of the Company, enforceable against the Company in accordance with its terms except (i) as
limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application
relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions
contained in the Registration Rights may be limited by applicable federal or state securities laws.

 

    5 

     

    

  

(d) Valid
Issuance of Securities. The Forward Purchase Units, when issued, sold and delivered in accordance with the terms and for the
consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable, as applicable, and free of all
preemptive or similar rights, taxes, liens, encumbrances and charges with respect to the issue thereof and restrictions on transfer
other than restrictions on transfer specified under this Agreement, applicable foreign, state and federal securities laws and liens
or encumbrances created by or imposed by the Purchaser. Assuming the accuracy of the representations of the Purchasers in this
Agreement and subject to the filings described in Section 3(e) below, the Forward Purchase Units will be
issued in compliance with all applicable federal, state and foreign securities laws.

 

(e) Governmental
Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in this Agreement, no consent, approval,
order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local
governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated
by this Agreement, except for filings pursuant to applicable state securities laws, if any, and pursuant to the Registration Rights.

 

(f) Compliance
with Other Instruments. The execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated by this Agreement will not result in any violation or default of any provisions of the Memorandum and Articles or
other governing documents of the Company, (ii) of any instrument, judgment, order, writ or decree to which the Company is
a party or by which it is bound, (iii) under any note, indenture or mortgage to which the Company is a party or by which it
is bound, (iv) under any lease, agreement, contract or purchase order to which the Company is a party or by which it is bound
or (v) of any provision of federal or state statute, rule or regulation applicable to the Company, in each case (other
than clause (i)) which would have a material adverse effect on the Company or its ability to consummate the transactions contemplated
by this Agreement.

 

(g) Operations.
As of the date hereof, the Company has not conducted, and prior to the IPO Closing the Company will not conduct, any operations
other than organizational activities and activities in connection with offerings of its securities.

 

(h) No
General Solicitation. Neither the Company, nor any of its officers, directors, employees, agents or shareholders has either
directly or indirectly, including, through a broker or finder (i) engaged in any general solicitation, or (ii) published
any advertisement in connection with the offer and sale of the Forward Purchase Units.

 

(i) No
Other Representations and Warranties; Non-Reliance. Except for the specific representations and warranties contained in
this Section 3 and in any certificate or agreement delivered pursuant hereto, none of the Company Parties
has made, makes or shall be deemed to make any other express or implied representation or warranty with respect to the Company,
this offering, the proposed IPO or a potential Business Combination, and the Company Parties disclaim any such representation or
warranty. Except for the specific representations and warranties expressly made by the Purchasers in Section 2 of
this Agreement and in any certificate or agreement delivered pursuant hereto, the Company Parties specifically disclaim that they
are relying upon any other representations or warranties that may have been made by the Purchaser Parties.

 

4. Registration Rights; Transfer

 

(a) Registration.
The Company agrees that the Purchasers shall have the registration rights set forth on Exhibit A.

 

(b) Indemnification.

 

    6 

     

    

 

(i) The
Company shall, notwithstanding any termination of this Agreement, indemnify, defend and hold harmless each Purchaser (to the extent
a seller under the Forward Registration Statement, as defined in Exhibit A), the officers, directors, agents, partners, members,
managers, stockholders, affiliates, employees and investment advisers of each Purchaser, each person who controls each Purchaser
(within the meaning of Section 15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)), and the officers, directors, partners, members, managers, stockholders, agents,
affiliates, employees and investment advisers of each such controlling person, to the fullest extent permitted by applicable law,
from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs of preparation
and investigation and reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred,
that arise out of or are based upon (i) any untrue or alleged untrue statement of a material fact contained in the Forward
Registration Statement, any prospectus included in the Forward Registration Statement or any form of prospectus or in any amendment
or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state
a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form
of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, or (ii) any
violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law or any rule or
regulation thereunder, in connection with the performance of its obligations under this Section 4, except to the
extent, but only to the extent, that such untrue statements, alleged untrue statements, omissions or alleged omissions are based
solely upon information regarding a Purchaser furnished in writing to the Company by such Purchaser expressly for use therein.

 

The Company shall notify
such Purchaser promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions
contemplated by this Section 4 of which the Company is aware. Such indemnity shall remain in full force and
effect regardless of any investigation made by or on behalf of an indemnified party and shall survive the transfer of the Registrable
Securities (as defined in Exhibit A) by the Company.

 

(ii) Each
Purchaser shall, severally and not jointly with any other selling shareholder named in the Forward Registration Statement, indemnify
and hold harmless the Company, its directors, officers, agents and employees, each person who controls the Company (within the
meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents
or employees of such controlling persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred,
arising out of or that are based upon any untrue or alleged untrue statement of a material fact contained in the Forward Registration
Statement, any prospectus included in the Forward Registration Statement, or any form of prospectus, or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein (in the case of any prospectus, or any form of prospectus
or supplement thereto, in light of the circumstances under which they were made) not misleading to the extent, but only to the
extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser furnished in writing
to the Company by such Purchaser expressly for use therein. In no event shall the liability of a Purchaser be greater in amount
than the dollar amount of the net proceeds received by such Purchaser upon the sale of the Registrable Securities giving rise to
such indemnification obligation.

 

(c) Transfer
Restrictions. The Purchasers agree that the Forward Purchase Securities are not transferable or salable until the completion
of the Business Combination, except (i) to any affiliate transferee, (ii) in the event of the Company’s liquidation
prior to the completion of the Business Combination, (iii) in the event of the Company’s completion of a liquidation,
merger, share exchange or other similar transaction which results in all of its Public Shareholders having the right to exchange
their Class A Ordinary Shares for cash, securities or other property subsequent to the completion of the Company’s initial
business combination; provided, however, that any such permitted transferee must enter into a written agreement agreeing to be
bound by the same transfer restrictions and the other restrictions contained in this Agreement with respect to the Forward Purchase
Securities and by the same agreements entered into by the Purchasers with respect to the Forward Purchase Securities. For purposes
of this Section 4(c), a transferee shall be deemed to be an “affiliate” of a Purchaser if such transferee directly,
or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, a Purchaser. The
Purchasers further agree that the Forward Purchase Shares and the Forward Purchase Warrants shall not be separately transferable
until the completion of the Business Combination.

 

5. Additional Agreements and
Acknowledgements of the Purchasers.

 

(a) Trust
Account.

 

    7 

     

    

 

(i) Each
Purchaser hereby acknowledges that it is aware that the Company will establish the Trust Account for the benefit of its public
shareholders upon the IPO Closing. Each Purchaser, for itself and its affiliates, hereby agrees that it has no right, title, interest
or claim of any kind in or to any monies held in the Trust Account, except for redemption and liquidation rights, if any, such
Purchaser may have in respect of any Public Shares, if any, held by it.

 

(ii) Each
Purchaser hereby agrees that it shall have no right of set-off or any right, title, interest or claim of any kind (“Claim”)
to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account
that it may have now or in the future, except for redemption and liquidation rights, if any, such Purchaser may have in respect
of any Public Shares held by it. In the event a Purchaser has any Claim against the Company under this Agreement, such Purchaser
shall pursue such Claim solely against the Company and its assets outside the Trust Account and not against the property or any
monies in the Trust Account, except for redemption and liquidation rights, if any, such Purchaser may have in respect of any Public
Shares held by it.

 

(b) Voting.
Each Purchaser hereby agrees that, if the Company seeks shareholder approval of a proposed Business Combination, then, in connection
with such proposed Business Combination, such Purchaser shall vote any Class A Ordinary Shares owned by it in favor of any
proposed Business Combination.

 

(c) No
Short Sales. Each Purchaser hereby agrees that neither it, nor any person or entity acting on its behalf or pursuant to any
understanding with it, will engage in any Short Sales with respect to securities of the Company prior to the Business Combination
Closing. For purposes of this Section, “Short Sales” shall include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct
and indirect share pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward
sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), each of such foregoing
instruments that is naked short, and short sales and other short transactions through non-U.S. broker dealers or foreign
regulated brokers.

 

6. Listing. The Company
will use commercially reasonable efforts to effect and maintain the listing of the Ordinary Shares and the Redeemable Warrants
on the Nasdaq Capital Market (or another national securities exchange).

 

7. Forward Closing Conditions.

 

(a) The obligation
of each Purchaser to purchase the Forward Purchase Units at a Forward Closing under this Agreement shall be subject to the fulfillment,
at or prior to such Forward Closing of each of the following conditions, any of which, to the extent permitted by applicable laws,
may be waived by the Purchaser:

 

(i) (A) With
respect to a Forward Closing occurring on the date of the Business Combination Closing, the Business Combination shall be consummated
substantially concurrently with the purchase of the Forward Purchase Units and (B) with respect to a Forward Closing occurring
prior to the date of the Business Combination Closing, Purchasers shall not have delivered to the Company a revocation of the Purchase
Election Notice with respect to such Forward Purchase;

 

(ii) The
Company shall have delivered to the Purchasers a certificate evidencing the Company’s good standing as a Cayman Islands exempted
company;

 

(iii) The
representations and warranties of the Company set forth in Section 3 of this Agreement shall have been true
and correct as of the date hereof and shall be true and correct as of such date of such Forward Closing (a “Forward
Closing Date”), as applicable, with the same effect as though such representations and warranties had been made on
and as of such date (other than any such representation or warranty that is made by its terms as of a specified date, which shall
be true and correct as of such specified date), except where the failure to be so true and correct would not have a material adverse
effect on the Company or its ability to consummate the transactions contemplated by this Agreement;

 

(iv) The
Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by the Company at or prior to such Forward Closing Date; and

 

(v) No
order, writ, judgment, injunction, decree, determination, or award shall have been entered by or with any governmental, regulatory,
or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition
shall be in effect, preventing the purchase by the Purchasers of the Forward Purchase Units.

 

    8 

     

    

 

 

(b) The obligation
of the Company to sell the Forward Purchase Units at a Forward Closing under this Agreement shall be subject to the fulfillment,
at or prior to such Forward Closing of each of the following conditions, any of which, to the extent permitted by applicable laws,
may be waived by the Company:

 

(i) (A) With
respect to a Forward Closing occurring on the date of the Business Combination Closing, the Business Combination shall be consummated
substantially concurrently with the purchase of the Forward Purchase Units and (B) with respect to a Forward Closing occurring
prior to the date of the Business Combination Closing, Purchasers shall not have delivered to the Company a revocation of the Purchase
Election Notice with respect to such Forward Purchase;

 

(ii) The
representations and warranties of the Purchasers set forth in Section 2 of this Agreement shall have been
true and correct as of the date hereof and shall be true and correct as of such Forward Closing Date, as applicable, with the same
effect as though such representations and warranties had been made on and as of such date (other than any such representation or
warranty that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except where
the failure to be so true and correct would not have a material adverse effect on the Purchasers or their ability to consummate
the transactions contemplated by this Agreement;

 

(iii) The
Purchasers shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with by the Purchasers at or prior to such Forward Closing; and

 

(iv) No
order, writ, judgment, injunction, decree, determination, or award shall have been entered by or with any governmental, regulatory,
or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition
shall be in effect, preventing the purchase by the Purchasers of the Forward Purchase Units.

 

8. Termination. This Agreement
may be terminated at any time:

 

(a) by mutual
written consent of the Company and the Purchaser; or

 

(b) automatically
if the Business Combination is not consummated within 24 months from the IPO Closing.

 

In the event of
any termination of this Agreement pursuant to this Section 8, any purchase price for Forward Purchase Units (and
interest thereon, if any), if previously paid, shall be promptly returned to the Purchasers, the Company shall ensure appropriate
instruments are executed to ensure that any holder of an Ordinary Share issued in the IPO will have no claim to such funds, and
thereafter this Agreement shall forthwith become null and void and have no effect, without any liability on the part of the Purchasers
or the Company and their respective directors, officers, employees, partners, managers, members, or shareholders and all rights
and obligations of each of the parties shall cease; provided, however, that nothing contained in this Section 8 shall
relieve either party from liabilities or damages arising out of any fraud or willful breach by such party of any of its representations,
warranties, covenants or agreements contained in this Agreement.

 

9. General Provisions.

 

(a) Notices. All notices and
other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the
earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic
mail or facsimile (if any) during normal business hours of the recipient, and if not sent during normal business hours, then on
the recipient’s next Business Day, (c) five (5) Business Days after having been sent by registered or certified
mail, return receipt requested, postage prepaid, or (d) one (1) Business Day after deposit with a nationally recognized
overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt. All communications
sent to the Company shall be sent to: Medicus Sciences Acquisition Corp., 152 West 57th Street, Floor 20, New York,
New York 10019, Attention: Mark Gottlieb and emailed to mgottlieb@altiumcap.com, with a copy sent to the Company’s
counsel at Ellenoff Grossman & Schole LLP, 1345 Avenue of the Americas, New York, New York 10105, Attention: Barry I.
Grossman, Esq. and Stuart Neuhauser, Esq., and emailed to bigrossman@egsllp.com and sneuhauser@egsllp.com.

 

    9 

     

    

 

All communications
to the Purchasers shall be sent to the Purchasers’ address as set forth on the signature page hereof, or to such e-mail address,
facsimile number (if any) or address as subsequently modified by written notice given in accordance with this Section 9(a).

 

(b) No
Finder’s Fees. Each of the parties represents that it neither is nor will be obligated for any finder’s fee or
commission in connection with this transaction. The Purchasers agree to indemnify and to hold harmless the Company from any liability
for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and
the costs and expenses of defending against such liability or asserted liability) for which the Purchasers or their respective
officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless the Purchasers from any
liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction
(and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers,
employees or representatives is responsible.

 

(c) Adjustments
to Notional Amounts. In the event of any change to the capital structure of the Company, whether dilutive or otherwise, by
way of a share dividend or share split, or any other dividend however described, the Forward Purchase Units will be adjusted to
account for such changes.

 

(d) Survival
of Representations and Warranties. All of the representations and warranties contained herein shall survive the consummation
of the transactions contemplated by this Agreement or (subject to Section 8 herein) the termination hereof.

 

(e) Entire
Agreement. This Agreement, together with any documents, instruments and writings that are delivered pursuant hereto or referenced
herein, constitute the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes
all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate
in any way to the subject matter hereof or the transactions contemplated hereby.

 

(f) Successors.
All of the terms, agreements, covenants, representations, warranties, and conditions of this Agreement are binding upon, and inure
to the benefit of and are enforceable by, the parties hereto and their respective successors. Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(g) Assignments.
Except as otherwise specifically provided herein, no party hereto may assign either this Agreement or any of its rights, interests,
or obligations hereunder without the prior written approval of the other party.

 

(h) Counterparts.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument.

 

(i) Headings.
The section headings contained in this Agreement are inserted for convenience only and will not affect in any way the meaning or
interpretation of this Agreement.

 

(j) Governing
Law. This Agreement, the entire relationship of the parties hereto, and any litigation between the parties (whether grounded
in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the
laws of the State of New York, without giving effect to its choice of laws principles.

 

(k) Jurisdiction.
The parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of New York and to the
jurisdiction of the United States District Court for the Southern District of New York for the purpose of any suit, action or other
proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising
out of or based upon this Agreement except in state courts of New York or the United States District Court for the Southern District
of New York, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit,
action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property
is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that
the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced
in or by such court.

 

    10 

     

    

 

(l) Waiver
of Jury Trial. The parties hereto hereby waive any right to a jury trial in connection with any litigation pursuant to this
Agreement and the transactions contemplated hereby.

 

(m) Amendments.
This Agreement may not be amended, modified or waived as to any particular provision, except with the prior written consent of
the Company and the Purchasers.

 

(n) Severability.
The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will not affect
the validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement,
as applied to any party hereto or to any circumstance, is adjudged by a governmental authority, arbitrator, or mediator not to
be enforceable in accordance with its terms, the parties hereto agree that the governmental authority, arbitrator, or mediator
making such determination will have the power to modify the provision in a manner consistent with its objectives such that it is
enforceable, and/or to delete specific words or phrases, and in its reduced form, such provision will then be enforceable and will
be enforced.

 

(o) Expenses.
Each of the Company and the Purchasers will bear its own costs and expenses incurred in connection with the performance of this
Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses of agents, representatives,
financial advisors, legal counsel and accountants. The Company shall be responsible for the fees of its transfer agent, stamp taxes
and all The Depository Trust Company fees associated with the issuance of the Forward Purchase Units.

 

(p) Construction.
The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of
intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption
or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement.
Any reference to any federal, state, local, or foreign law will be deemed also to refer to law as amended and all rules and
regulations promulgated thereunder, unless the context requires otherwise. The words “include,” “includes,”
and “including” will be deemed to be followed by “without limitation.” Pronouns
in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be
construed to include the plural and vice versa, unless the context otherwise requires. The words “this Agreement,”
 “herein,” “hereof,” “hereby,” “hereunder,”
and words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited.
The parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance.
If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there
exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity)
which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the
first representation, warranty, or covenant.

 

(q) Waiver.
No waiver by any party hereto of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional
or not, may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder
or affect in any way any rights arising because of any prior or subsequent occurrence.

 

(r) Specific
Performance. The Purchasers agree that irreparable damage may occur in the event any provision of this Agreement was not performed
by the Purchasers in accordance with the terms hereof and that the Company shall be entitled to seek specific performance of the
terms hereof, in addition to any other remedy at law or equity.

 

[Signature Page Follows]

 

    11 

     

    

 

IN WITNESS
WHEREOF, the undersigned have executed this Agreement to be effective as of the date first set forth above.

 

	 	PURCHASERS:  
	 	 
	 	ALTIUM MSAC, LLC   
	 	 
	 	By:	Altium Growth Fund, LP, its sole member
	 	By:	Altium Capital Management, LP, its investment manager
	 	 	 
	 	By:	/s/ Mark Gottlieb
	 	 	Name: Mark Gottlieb
	 	 	Title:   Authorized Signatory

 

	 	Address: 	152 W 57th St FL 20
	 	 	New York, NY 10019

 

	 	STRUCTURE ALPHA LLC
	 	 
	 	By:	Sio Capital Management, LLC, its investment manager
	 	 	 
	 	By:	/s/ Michael Castor
	 	 	Name: Michael Castor
	 	 	Title:   Managing Member

 

	 	Address: 	152 W 57th St FL 20
	 	 	New York, NY 10019

 

	 	COMPANY:
	 	 
	 	MEDICUS SCIENCES ACQUISITION CORP.
	 	 
	 	By:	/s/ Michael Castor
	 	 	Name: Michael Castor
	 	 	Title:   Chief Executive Officer

 

[Signature Page to
Forward Purchase Agreement]

 

    12 

     

    

 

 

EXHIBIT A

 

REGISTRATION
RIGHTS

 

	1.	The Company shall (i) use commercially reasonable efforts to file within fifteen (15) Business Days after the Business Combination Closing a registration statement on Form S-3 for a secondary offering (including any successor registration statement covering the resale of the Registrable Securities, a “Forward Registration Statement”) of (x) the Forward Purchase Units, (y) any other equity security of the Company issued or issuable with respect to the securities referred to in clause (x) by way of a share dividend or share split or by way of a conversion from a warrant, or by way of a separation of the units into ordinary shares and warrants, or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization and (z) any other shares or warrants of the Company that the Purchasers may have purchased in the open market (collectively, the “Registrable Securities”) pursuant to Rule 415 under the Securities Act; provided that, if Form S-3 is unavailable for such a registration, the Company shall register the resale of the Registrable Securities on another appropriate form and undertake to register the Registrable Securities on Form S-3 as soon as such form is available, (ii) use best efforts to cause the Forward Registration Statement to be declared effective under the Securities Act as soon as practicable thereafter, but in no event later than sixty (60) Business Days thereafter, and (iii) use commercially reasonable efforts to maintain the effectiveness of such Forward Registration Statement with respect to the Registrable Securities until the earlier of (A) the date on which the Purchasers cease to hold Registrable Securities covered by such Forward Registration Statement and (B) the date all of the Registrable Securities covered by the Forward Registration Statement can be sold publicly without restriction or limitation under Rule 144 under the Securities Act and without the requirement to be in compliance with Rule 144(c)(1) under the Securities Act.

 

	2.	In the event the Company is prohibited by applicable rule, regulation or interpretation by the staff (“Staff”) of the Securities and Exchange Commission (“SEC”) from registering all of the Registrable Securities on a Forward Registration Statement or the Staff requires that each Purchaser be specifically identified as an “underwriter” in order to permit such registration statement to become effective, and such Purchaser does not consent in writing to being so named as an underwriter in such registration statement, the number of Registrable Securities to be registered on such Forward Registration Statement will be reduced on a pro rata basis among all the holders of Registrable Securities to be so included, unless otherwise required by the Staff, so that the number of Registrable Securities to be registered is permitted by the Staff and such Purchaser is not required to be named as an “underwriter”; provided, that any Registrable Securities not registered due to this paragraph 2 of this Exhibit A shall thereafter as soon as allowed by the SEC guidance be registered to the extent the prohibition no longer is applicable.

 

	3.	If at any time the Company proposes to file a registration statement (a “Registration Statement”) on its own behalf, or on behalf of any other Persons who have registration rights (“Other Holders”), relating to an underwritten offering of shares, or engage in an underwritten takedown off an existing registration statement (a “Company Offering”), then the Company will provide the Purchasers (collectively, the “Piggyback Holders”) with notice in writing (an “Offer Notice”) at least five (5) Business Days prior to such filing, which Offer Notice will offer to include in the Registration Statement a minimum amount of Registrable Securities of the Purchasers as reasonably and mutually determined by the Company and the Purchaser at such time (collectively “Piggyback Securities”). Within five (5) Business Days (or, in the case of an Offer Notice delivered to the Piggyback Holders in connection with an underwritten takedown, within three (3) Business Days) after receiving the Offer Notice, the Piggyback Holders may make a written request (a “Piggyback Request”) to the Company to include some or all of the Piggyback Holders’ Registrable Securities in the Registration Statement. If the underwriter(s) for any Company Offering advise the Company that marketing factors require a limitation on the number of securities that may be included in the Company Offering: (A) if the Registration Statement relating to the Company Offering is to be filed on behalf of the Company then the number of securities to be so included shall be allocated as follows (i) first, to the Company; and (ii) second, to the Piggyback Holders and holders of Class A Ordinary Shares or other equity securities of the Company or other persons or entities that the Company is obligated to register in a Registration pursuant to separate written contractual arrangements with such persons (pro rata based on the respective number of Registrable Securities held by such person prior to the applicable Company Offering); and (B) if the Registration Statement relating to the Company Offering is to be filed on behalf of Other Holders then the number of securities to be so included shall be allocated as follows: (i) first to such Other Holders; (ii) second, to the Piggyback Holders and holders of Class A Ordinary Shares or other equity securities of the Company other persons or entities that the Company is obligated to register in a Registration pursuant to separate written contractual arrangements with such persons (pro rata based on the respective number of Registrable Securities held by such person prior to the applicable Company Offering); and (iii) third, to the Company. Notwithstanding anything to the contrary in this paragraph 3, the Company hereby agrees that it will not provide an Offer Notice to any Piggyback Holder unless such Piggyback Holder agrees in writing to treat the contents of such Offer Notice as material non-public information.

 

    13 

     

    

 

	4.	The determination of whether any offering of Registrable Securities pursuant to a Forward Registration Statement will be an underwritten offering shall be made in the sole discretion of the Purchasers, after consultation with the Company, and the Purchasers shall have the right, after consultation with the Company, to determine the plan of distribution, including the price at which the Registrable Securities are to be sold and the underwriting commissions, discounts and fees. The Purchasers shall select the investment banker or bankers and managers to administer the offering, including the lead managing underwriter (provided that such investment banker or bankers and managers shall be reasonably satisfactory to the Company).

 

	5.	In connection with any underwritten offering, the Company shall enter into such customary agreements and take all such other actions in connection therewith (including those requested by the Purchasers) in order to facilitate the disposition of such Registrable Securities as are reasonably necessary or required, and in such connection enter into a customary underwriting agreement that provides for customary opinions, comfort letters and officer’s certificates and other customary deliverables.

 

	6.	The Company shall pay all fees and expenses incident to the performance of or compliance with its obligation to prepare, file and maintain each Forward Registration Statement (including the fees of its counsel and accountants). The Company shall also pay all Registration Expenses. For purposes of this paragraph 6, “Registration Expenses” shall mean the out-of-pocket expenses of the Purchasers and Company in connection with each Forward Registration Statement and offerings thereunder, including, without limitation, the following: (i) all registration and filing fees (including fees with respect to filings required to be made with FINRA) and any securities exchange on which the Registrable Securities are then listed; (ii) fees and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the underwriters in connection with blue sky qualifications of the Registrable Securities); (iii) printing, messenger, telephone and delivery expenses; (iv) reasonable fees and disbursements of counsel for Purchasers and the Company; and (v) reasonable fees and disbursements of all independent registered public accountants of the Company incurred specifically in connection with such Forward Registration Statement and offering thereunder.

 

	7.	The Company may suspend the use of a prospectus included in a Forward Registration Statement by furnishing to the Purchasers a written notice (“Suspension Notice”) stating that in the good faith judgment of the Company, it would be either (i) prohibited by the Company’s insider trading policy (as if the Purchasers were covered by such policy) or (ii) materially detrimental to the Company and its shareholders for such prospectus to be used at such time. The Company’s right to suspend the use of such prospectus under clause (ii) of the preceding sentence may be exercised for a period of not more than sixty (60) days after the date of such notice to the Purchaser; provided such period may be extended for an additional thirty (30) days with the consent of a majority-in-interest of the holders of Registrable Securities covered by such Forward Registration Statement, which consent shall not be unreasonably withheld; provided further, that such right to suspend the use of a prospectus shall be exercised by the Company not more than once in any twelve (12) month period. A holder of Registrable Securities shall not effect any sales of Registrable Securities pursuant to a Forward Registration Statement at any time after it has received a Suspension Notice from the Company and prior to receipt of an End of Suspension Notice (as defined below). The holders may recommence effecting sales of the Registrable Securities pursuant to such Forward Registration Statement following further written notice to such effect (an “End of Suspension Notice”) from the Company to the holders. The Company shall act in good faith to permit any suspension period contemplated by this paragraph to be concluded as promptly as reasonably practicable.

 

	8.	Each Purchaser agrees that, except as required by applicable law, such Purchaser shall treat as confidential the receipt of any Suspension Notice (provided that in no event shall such notice contain any material nonpublic information of the Company) hereunder and shall not disclose or use the information contained in such Suspension Notice without the prior written consent of the Company until such time as the information contained therein is or becomes public, other than as a result of disclosure by a holder of Registrable Securities in breach of the terms of this Agreement.

 

    14 

     

    

 

	9.	The Company’s obligation under paragraph 1 of this Exhibit A is subject to the Purchasers’ furnishing to the Company in writing such information as the Company reasonably requests for use in connection with a Forward Registration Statement, the related prospectus, or any amendment or supplement thereto.

 

	10.	The Company shall cooperate with the Purchasers, to the extent the Registrable Securities become freely tradable, to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant to a Forward Registration Statement and enable such certificates to be in such denominations or amounts, as the case may be, as the Purchasers may reasonably request and registered in such names as the Purchasers may request.

 

	11.	If requested by a Purchaser, the Company shall as soon as practicable, subject to any Suspension Notice, (i) incorporate in a prospectus supplement or post-effective amendment such information as such Purchaser reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering; (ii) make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration Statement if reasonably requested by the Purchasers holding any Registrable Securities.

 

	12.	As long as a Purchaser shall own Registrable Securities, the Company, at all times while it shall be reporting under the Securities Exchange Act of 1934, as amended, covenants to file all reports required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and to promptly furnish the Purchasers with true and complete copies of all such filings, unless filed through the SEC’s EDGAR system. The Company further covenants that it shall take such further action as the Purchasers may reasonably request, all to the extent required from time to time, to enable the Purchasers to sell the Class A Shares and warrants held by the Purchasers without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 promulgated under the Securities Act, including providing any legal opinions. Upon the request of a Purchaser, the Company shall deliver to such Purchaser a written certification of a duly authorized officer as to whether it has complied with such requirements.

 

	13.	The rights, duties and obligations of the Purchasers under this Exhibit A may be assigned or delegated by the Purchasers in conjunction with and to the extent of any permitted transfer or assignment of Registrable Securities by the Purchasers to any permitted transferee or assignee.

 

Exhibit A-4

 

    15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]